Bellwether Investment Group LLC reduced its position in shares of Allergan PLC. (NYSE:AGN) by 0.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,379 shares of the company’s stock after selling 3 shares during the quarter. Allergan PLC. comprises 2.7% of Bellwether Investment Group LLC’s portfolio, making the stock its 7th largest holding. Bellwether Investment Group LLC’s holdings in Allergan PLC. were worth $578,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of AGN. Waldron LP bought a new position in Allergan PLC. during the 1st quarter valued at $348,000. Adell Harriman & Carpenter Inc. boosted its stake in shares of Allergan PLC. by 52.9% during the 1st quarter. Adell Harriman & Carpenter Inc. now owns 23,310 shares of the company’s stock worth $5,569,000 after acquiring an additional 8,069 shares in the last quarter. Grimes & Company Inc. boosted its stake in shares of Allergan PLC. by 14.5% during the 1st quarter. Grimes & Company Inc. now owns 14,224 shares of the company’s stock worth $3,399,000 after acquiring an additional 1,799 shares in the last quarter. Pillar Pacific Capital Management LLC boosted its stake in shares of Allergan PLC. by 11.0% during the 1st quarter. Pillar Pacific Capital Management LLC now owns 18,070 shares of the company’s stock worth $4,318,000 after acquiring an additional 1,797 shares in the last quarter. Finally, Chicago Equity Partners LLC boosted its stake in shares of Allergan PLC. by 1,614.8% during the 1st quarter. Chicago Equity Partners LLC now owns 26,150 shares of the company’s stock worth $6,248,000 after acquiring an additional 24,625 shares in the last quarter. 82.02% of the stock is owned by hedge funds and other institutional investors.

Allergan PLC. (AGN) opened at 221.54 on Tuesday. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The stock has a 50 day moving average price of $230.85 and a 200-day moving average price of $236.29. The company has a market capitalization of $74.06 billion, a price-to-earnings ratio of 6.75 and a beta of 1.18.

Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. Allergan PLC.’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.35 EPS. Equities analysts predict that Allergan PLC. will post $16.25 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were issued a $0.70 dividend. The ex-dividend date was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.26%. Allergan PLC.’s payout ratio is 9.95%.

ILLEGAL ACTIVITY WARNING: “Allergan PLC. (AGN) Holdings Cut by Bellwether Investment Group LLC” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/19/allergan-plc-agn-holdings-cut-by-bellwether-investment-group-llc.html.

Several research firms have recently weighed in on AGN. Vetr raised Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price objective for the company in a research note on Monday, June 26th. BidaskClub lowered Allergan PLC. from a “sell” rating to a “strong sell” rating in a research note on Friday, August 25th. Royal Bank Of Canada set a $284.00 price objective on Allergan PLC. and gave the stock a “buy” rating in a research note on Monday, June 12th. Mizuho reissued a “buy” rating and set a $267.00 price objective on shares of Allergan PLC. in a research note on Wednesday, August 2nd. Finally, Argus reissued a “buy” rating and set a $280.00 price objective on shares of Allergan PLC. in a research note on Monday, August 14th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $274.69.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.